# Evidence Summary ### Berberine Research Overview 1. Extensive preclinical data across colorectal, breast, gastric, lung, liver, pancreatic, brain, and melanoma models 2. Repeat mechanism findings across apoptosis, cell-cycle arrest, autophagy, invasion control, and inflammatory signalling 3. Combination studies showing chemosensitisation and radiosensitisation interest in selected models 4. Limited human oncology data, with most clinical evidence still indirect or early-stage 5. Strong non-oncology human data for metabolic use, which helps with safety and dose context ### Clinical Application Status **Approved status:** Marketed as a supplement and botanical alkaloid ingredient. **Clinical use:** Used in integrative settings mainly for metabolic, microbial, and inflammation-linked questions. In oncology, it is best framed as an investigational adjunct. **Evidence strength:** Strong preclinical evidence. Limited human oncology evidence. Best positioned as a combination-support or mechanism-led adjunct, not a monotherapy. {% stepper %} {% step %} > Berberine shows broad anticancer activity in cell and animal studies across several tumour types. The most consistent findings involve apoptosis, cell-cycle arrest, invasion control, inflammatory pathway suppression, and treatment sensitisation. Human oncology data remains limited, so berberine should be treated as promising but still investigational. Interaction risk and dose timing matter. > {% endstep %} > {% endstepper %} ### Cancer Settings with Stronger Preclinical Signal * **Colorectal cancer** — strong mechanistic depth and likely exposure advantage in the gut * **Breast cancer** — apoptosis, G1 arrest, and tamoxifen-sensitisation findings * **Gastric cancer** — repeated work on STAT3, EGFR, and cisplatin sensitisation * **Liver cancer** — apoptosis and radiosensitisation interest * **Pancreatic cancer** — metabolic stress and PARP-inhibitor synergy interest * **Lung cancer** — apoptosis, invasion suppression, and formulation-led work * **Glioma** — early but biologically relevant signal * **Melanoma** — autophagic cell-death signalling is especially noted ### Key Advantages 1. **Multi-pathway activity** — affects proliferation, apoptosis, metabolism, invasion, and inflammatory signalling together 2. **Combination relevance** — can sensitise selected tumour models to chemotherapy, endocrine therapy, PARP inhibition, and radiation 3. **GI and metabolic relevance** — may be especially interesting where gut and liver exposure matter 4. **Large supportive safety literature** — non-oncology human studies give useful tolerability context 5. **Formulation innovation** — newer delivery systems may overcome part of the bioavailability problem ### Key Considerations 1. **Human evidence gap** — most oncology data remains preclinical 2. **Bioavailability limitations** — standard oral berberine has poor systemic exposure 3. **Interaction burden** — CYP3A4 and P-glycoprotein effects can matter clinically 4. **Dose-response complexity** — low and high doses may not behave the same way 5. **Potential hormesis issue** — low-dose berberine may reduce sensitivity to some cytotoxics in selected preclinical settings ### Practical Dose Context Human studies outside oncology commonly use **500 to 1500 mg daily** in divided doses. That does **not** establish an optimal oncology dose. It does provide rough tolerability context. Oncology-specific timing, duration, and formulation remain unsettled. ### Where to Go Next * [Berberine in Oncology Overview](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms.md) * [Berberine Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/immune-effects.md) * [Antimicrobial / Antifungal Activity](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/antimicrobial-antifungal-activity.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/pharmacokinetics-and-metabolism.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/dosing-and-timing.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/safety-and-interactions.md) * [Berberine & Metformin](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-and-metformin.md) * [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/redox-dual-action.md) ### Key References Berberine as a Potential Anticancer Agent: A Comprehensive Review\ PMC Full Text:[ PMC8658774](https://pmc.ncbi.nlm.nih.gov/articles/PMC8658774/) Islam MN et al. (2021). Molecules, 26(23):7368.[ PMC8658774](https://pmc.ncbi.nlm.nih.gov/articles/PMC8658774/) Sajeev A et al. (2024). Cancer Letters, 597:217019.[ doi.org/10.1016/j.canlet.2024.217019](https://doi.org/10.1016/j.canlet.2024.217019) Feng X et al. (2022). Evid Based Complement Alternat Med, 2022:1189034.[ PMC9316001](https://pmc.ncbi.nlm.nih.gov/articles/PMC9316001/) Evidence-Based Complementary and Alternative Medicine (Hindawi/Wiley) — Open Access \ PMC Full Text:[ PMC9316001](https://pmc.ncbi.nlm.nih.gov/articles/PMC9316001/) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/evidence-summary.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.